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Background
The capacity of Ab to alter antigen uptake and processing
resulting in enhanced or suppressed antigen presentation
has been demonstrated with a number of antigens,
including tetanus toxoid, β-galactoside, apo-cytochrome
c, and HIV-1 envelope glycoproteins [1–6]. In the case of
HIV-1, the inhibitory activity is correlated with the serum
Ab titers to the CD4-binding site (CD4bs) of gp120 [7]. In
fact, by screening a panel of human anti-gp120 mAb, we
ascertained that this inhibitory activity is mediated by Ab
to the CD4bs; Ab to V2, V3, C2, or C5 did not exhibit such
effect [1]. In previous studies only high affinity anti-
CD4bs mAb were examined; these mAb completely block
MHC class II presentation of gp120 antigens [1, 2]. How-
ever, it is not known if all anti-CD4bs Ab equally mediate
such a strong inhibition. Since gp120/mAb complex for-
mation was shown to be critical for anti-CD4bs mAb to
block gp120 processing and presentation [1, 2], we postu-
lated that the Ab affinity could be a key determinant for
their suppressive activity.
Material and methods
In the present study we selected a panel of six anti-CD4bs
mAb with different relative affinities for gp120, and exam-
ined their ability to suppress gp120 presentation to CD4
T cells. In addition, we tested CD4i mAb binding to the
chemokine-receptor-binding site that, similar to anti-
CD4bs mAb, were previously reported to render gp120
more resistant to degradative enzymes [7]. For compari-
son, a mAb specific for a conformation-dependent
epitope outside the receptor binding sites and a relatively
high affinity anti-V3 mAb were also tested. The ability of
each of these mAb to suppress class II antigen presenta-
tion to gp120-specific CD4 T cells was correlated with the
mAb affinity for gp120. The uptake of gp120 by APC was
also evaluated in the presence of these mAb. Furthermore,
we measured the stability of the mAb-gp120 interaction at
acidic pH representing the endolysosomal environment
in APC and quantified the effect of the mAb on the rate of
gp120 proteolytic processing by lysosomal enzymes in
vitro.
Results
Anti-CD4bs antibodies that completely obstruct gp120
presentation exhibit three common properties: relatively
high affinity for gp120, acid stable interaction with
gp120, and the capacity to slow the kinetics of gp120 pro-
teolytic processing. None of these antibodies prevents
gp120 internalization into APC.
Conclusion
The present studies demonstrate that poorly neutralizing
anti-CD4bs Ab produced by chronically HIV-1 infected
patients prevent the stimulation of gp120-specific CD4 T
cell responses. These Ab form relatively stable high-affin-
ity immune complexes, which are resistant to proteolytic
processing by lysosomal enzymes. The presence of such
Ab in sera of HIV-1-infected patients may contribute to
the dearth of helper CD4 T responses to the virus envelope
antigens and consequently weaken the anti-viral immu-
from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005
Published: 8 December 2005
Retrovirology 2005, 2(Suppl 1):P100 doi:10.1186/1742-4690-2-S1-P100
<supplement> <title> <p>2005 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. [link 'here' using 'a href' to: <url>http://www.biomedcentral.com/content/pdf/1742-4690-2-S1-full. df</url>]</not /supplement>Page 1 of 2
(page number not for citation purposes)
Retrovirology 2005, 2:P100Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
nity necessary to control the chronic HIV infection and
disease.Page 2 of 2
(page number not for citation purposes)
